Brussels, February 10, 2026 –
React4Life, alongside leading European innovators, announces the creation of the Industry Alliance for Microphysiological Systems (IAMPS), the world’s first industry association dedicated to representing MPS providers. This milestone positions Europe—and Italian biotech expertise—at the forefront of a strategic shift toward human-relevant science.
What Is IAMPS and Why It Matters for Europe
IAMPS brings together European companies developing microphysiological systems (MPS)—advanced human biology-based models including organoids and organs-on-chips—that faithfully replicate human tissue and organ functions. As New Approach Methodologies (NAMs), MPS offer significantly higher predictive accuracy than traditional animal models or simplistic 2D systems.
This technology directly supports critical EU policy objectives: phasing out animal testing in toxicology, improving public health outcomes, reducing animal use in research, and strengthening Europe’s competitiveness in the global life sciences sector.
React4Life’s Role in Shaping Europe’s MPS Future
As a founding member representing Italian innovation in microphysiological systems, React4Life joins this pan-European initiative to overcome shared industry challenges. Despite growing adoption by academic and industrial end-users, MPS providers face hurdles in scaling accessibility and gaining broader regulatory acceptance.
IAMPS will address these challenges through five strategic priorities:
- Regulatory collaboration: Working with EMA, FDA, MHRA and other agencies to increase acceptance of MPS-derived data and advance the EU Life Science Strategy’s goal of derisking clinical trials
- Data-sharing platforms: Creating collaborative frameworks between MPS developers, pharmaceutical companies and CROs to build retrospective case studies on predictive value
- Standardization: Advancing qualification and harmonization of MPS devices with EU agencies including EMA and the European Centre for the Validation of Alternative Methods
- EU funding alignment: Ensuring Horizon Europe and the European Competitiveness Fund recognize MPS development as a strategic industrial priority
- European biobanking: Securing reliable domestic sources of cells and tissues to reflect population diversity while guaranteeing EU industrial autonomy
A Call for European Leadership in Human-Relevant Science
With well-funded U.S. initiatives accelerating—such as NIH’s Complement Animal Research Experimentation (CARe) program and the Standardized Organoids Modeling Center—IAMPS calls for a decisive European response to secure the continent’s leadership in this strategic field.
The founding members, including React4Life and other European pioneers, are committed to establishing MPS as a strategic technology for Europe through collective action and policy engagement.
CEO Perspective: Italian Innovation at the Heart of European Sovereignty
Maurizio Aiello, CEO of React4Life, commented on the alliance:
“The launch of IAMPS responds to the need for more predictive, human-relevant, and scientifically robust models for biomedical research and drug evaluation. Technologies such as organ-on-chip systems offer the opportunity to enhance the quality of biomedical decision-making and strengthen the competitiveness of the European innovation ecosystem. When leading companies join forces, they do not merely share a common vision; they build the ecosystem that will make these innovations acceptable to regulators, scalable for industry, and accessible to the research community. For an Italian company, this represents the opportunity to transform scientific excellence into tangible influence on the policies that will shape the medicine of the future.”
Looking Ahead
React4Life’s participation in IAMPS underscores Italy’s commitment to advancing next-generation biomedical tools within a unified European framework. By aligning regulatory pathways, funding mechanisms, and industrial capabilities, IAMPS will accelerate the adoption of MPS across drug development, toxicology, and personalized medicine—ensuring Europe remains at the forefront of ethical, predictive, and human-centric science.
For media inquiries: press@react4life.com; contact@iamps.eu